Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Best Pharma Stocks To Buy + Sector Update By Emkay



Emkay has conducted a detailed study of the Q2CY15 DMF filings by top pharma companies and identified the stocks to buy and hold




Q2 CY15 DMF filings reveal Indian companies have filed for 36% of total filings in Q2 CY15, much lower than the 45% aggregate in 2014 and 47% in 2013. Cumulatively Indian companies filed for 45 molecules in Q2 CY15 compared to 96 in Q1 CY15

Cipla and Alembic file DMF on generics with low competition products –Ambrisentan and Azilsartan respectively. Cipla also filed Albendazole which is off patent but has no generic. Aurobindo, the only Indian filer for injectable for the quarter

Click here to download Emkay’s Pharma sector update
investments, Large Cap, Mid Cap, Portfolio, Top Picks    ,

4 Comments
  1. amit's Gravatar amit
    July 15, 2015 at 7:41 pm | Permalink

    DOLLY KHANNA and ANIL KUMAR GOEL make a big bang entry In RSWM.. Check latest June 2015 shareholding pattern..

    Reply
    • n samraj's Gravatar n samraj
      July 16, 2015 at 2:57 pm | Permalink

      she will also enter kpr mill, sutlej textiles, trident industries

      Reply
  2. amit's Gravatar amit
    July 15, 2015 at 7:52 pm | Permalink

    I think they were drunk while making this report. They said buy and target is negative hell. Company is paying them for writing shit

    Reply
    • mayur's Gravatar mayur
      July 16, 2015 at 5:00 pm | Permalink

      haha..yes noticed same thing…retail investors also paying for negative targets…Bullshit

      Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 493 other subscribers

RSS Stocks Talk Forum

  • Shalby is a multi-specialty hospital chain with expertise in joint replacement
    Shalby is a multi-specialty hospital chain with expertise in joint replacement. It is making right strides with calibrated growth based on big ticket expansion in metros & tier I cities & asset-light franchisee expansion in tier II-VI towns. TP ₹310 (35%) Download... Shalby is a multi-specialty hospital chain with expertise in joint replacement
  • DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
    DLF has strong growth prospects due to strong sectoral tailwinds, record low inventory, greater preference for branded luxury, extensive launch pipeline & expansion in its annuity portfolio. Strong Balance Sheet with consistent cash flow. TP ₹1081 (+30%) Research Report... DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
  • Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
    Aditya Birla Capital has demonstrated solid performance, achieving strong growth in the loan book while maintaining asset quality. Management has reiterated guidance on both growth & credit cost fronts. Lending business expected to grow at 30%. TP (+37%)... Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!